Orthofix Medical

Orthofix Medical

Orthofix Medical was founded in 1987, originally as a fracture-management business built around external fixation devices. Chief Executive Massimo Calafiore, appointed in January 2024, previously led the Global Spine division and steered the company through the SeaSpine combination. The underlying capital is public equity — Orthofix trades on Nasdaq under the symbol OFIX — with no single-family wealth origin. The company deploys across three orthopedics verticals: bone-growth therapies, spinal implants, and biologics for surgical repair. Strategic focus lies in the lumbar and cervical spine markets, where Orthofix sells hardware alongside its pulsed electromagnetic field stimulation system, Cervical-Stim. The 2023 merger with SeaSpine added a demineralized bone matrix portfolio and a suite of interbody fusion cages. Core commercial footprints are North America and Europe, with a major operational hub in Verona, Italy. Named co-development partners include nView medical for AI-powered surgical imaging — a deal struck in 2022 — and the broader Globus Medical competitive ecosystem. Orthofix employs roughly 1,600 people across Lewisville, Verona, Carlsbad, and field offices. The company operates an adjacent medical education program through Orthofix Academy, which trains surgeons on the 7D Surgical FLASH navigation system. In fiscal 2023, Orthofix reported total net sales of $747 million. In May 2024, Calafiore reorganized the commercial leadership layer, appointing a new President of Global Spine who reports directly. The structural differentiator is vertical integration of regenerative biologics with proprietary active-implant hardware. Unlike pure-play spinal competitors that buy donor tissue from tissue banks, Orthofix owns the full PTI-501 bone graft manufacturing chain. This controls quality and margin in a segment that reimburses surgeons per procedure rather than per implant list price — making procurement discipline a genuine competitive lever.